Biogen Inc


The Answer to Big Pharma's Biggest Problem Could Double Your Money in Just Three Years

You could forgive drug and biotech executives for having a bad case of target fixation.

After all, they do work in a field that is filled with time-consuming and expensive headaches.

Consider that the Biotechnology Innovation Organization (BIO), the world's largest biotech trade organization, looked at 7,400 drug programs by 1,103 companies. They were investigating drug-approval rates.

The news was not good -just 9.6% of drugs scientists discover ever get approved for sale. That's a one-in-ten shot.

With such daunting data, it's no wonder that, even in a field already worth $1.2 trillion in global sales, industry leaders are on the lookout for ways to lower the cost of discovery and shorten time to market.

And with that goal in mind, I've uncovered a high-octane, large-cap firm that has become an essential ingredient in the drug sector's success.

It's a cloud-based leader in pharmaceutical efficiency that has a history of crushing the market by no small measure.

And it's been doubling its earnings, on average, every 18 months...


Three Biotech Stocks Poised to Break Out

With recession indicators flashing, investors are flocking to 10-year bonds that have the annual upside of just 1.5%.

But there are still market-beating stocks out there – in fact, one of our picks expects 103% growth.

And that brings us to the biotech industry.

There are some big biotech stocks to own right now that could deliver double, even triple-digit upside in less than 12 months.

Read more here...

Wall Street

What Wall Street Gets Wrong About the Inverted Yield Curve

Things that'll be "different this time" usually aren't, especially when it comes to hot stoves, hot steering wheels, and hot bond markets. Touch 'em and you'll get burned, or so goes the thinking.

Every once in a while, though, the situation plays out.

Take the inverted yield curve that caused last Friday's vicious selloff and made countless headlines around the world when it happen for the first time since 2007.

Contrary to what Wall Street and legions of economists want you to believe, it may NOT be the harbinger of doom that it's been for the past 50 years.

Here's my case (and what to buy if you're interested in big profits)

Read More…


2 More Biotech Stocks Are Flashing Buy Signals Today

At the end of 2018, the Federal Reserve told the market the water was warm, come in for a swim.

The market was happy to oblige. In fact, the S&P 500 has rebounded almost 11% to start 2019, nearly erasing all of the losses from December.

It's as if the sell-off never happened.

Right now, the market is an absolute dream for stock pickers. And biotech stocks in particular are looking incredibly lucrative...